Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

(2012) J Iqbal et al.   BRITISH JOURNAL OF CANCER

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

(2011) P. M. L. H. Vencken et al.   ANNALS OF ONCOLOGY

Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers

(2011) Larissa J. Lee et al.   CANCER

Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy

(2011) Amir Sonnenblick et al.   CANCER BIOLOGY & THERAPY

Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers

(2011) Marieke A. Vollebergh et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

In Situ DNA Repair Assays As Guides to Personalized Breast Cancer Chemotherapeutics: Ready for Prime Time?

(2011) Rebecca A. Dent et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Prognosis inBRCA1andBRCA2Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study

(2011) Pamela J. Goodwin et al.   JOURNAL OF CLINICAL ONCOLOGY

An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions

(2011) M. A. Lowery et al.   ONCOLOGIST

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

(2010) Stephen B. Edge et al.   ANNALS OF SURGICAL ONCOLOGY

Upper Gastrointestinal Cancer Predisposition Syndromes

(2010) Manish A. Shah et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

(2010) Peter Bouwman et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors

(2009) B. Evers et al.   CLINICAL CANCER RESEARCH

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

(2009) Elizabeth Poplin et al.   JOURNAL OF CLINICAL ONCOLOGY

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

(2008) David S.P. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY

BRCAGermline Mutations in Jewish Patients With Pancreatic Adenocarcinoma

(2008) Cristina R. Ferrone et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect ofBRCA1/2Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer

(2007) Angela Chetrit et al.   JOURNAL OF CLINICAL ONCOLOGY